- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02466828
qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.
Quantitative Blood Oxygenation Level Dependent (qBOLD) MR Imaging of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.
Glioblastoma multiforme (GBM) is the most common primary malignant brain neoplasm in adults. Despite recent diagnostic and therapeutic advances, including aggressive surgical resection and chemoradiation, the prognosis of GBM has improved only slightly over the past two decades, with median survival of approximately 15 months. Tumor hypoxia is a feature of GBM that contributes to poor outcome through multiple mechanisms such as 1) overexpression of enzymes that play roles in temozolomide resistance, the main chemotherapeutic agent in GBM and 2) increase expression of cancer stem cells which are more resistant to radiation. Hypoxic tumour regions are associated with higher rates of progression and recurrence.
In this study the investigators will use an advanced MRI technique called qBOLD to non-invasively measure oxygenation in GBM and obtain targeted biopsies. The investigators take advantage of physical characteristics of Ferumoxytol (Feraheme®) which is an iron supplement, and utilize two recent technical advances not previously used in human tumours to quantitatively measure oxygenation in GBM.
Prior knowledge of hypoxia can assist in prognostication and individualization of treatment planning with special focus on hypoxic regions by targeted radiation dose or regimen modulation; consideration of more intensive chemotherapy regimens; more aggressive and targeted surgical resection and closer short-term clinical and imaging follow-ups.
Study Overview
Detailed Description
We propose a study to demonstrate quantitative oxygen saturation estimation in GBM is feasible with qBOLD and it correlates with established histopathological markers of hypoxia and angiogenesis, and targeted intraoperative oxygen measurement.
All patients will undergo surgery as part of their standard treatment. By coregistering the hypoxia map on presurgical MRI we will be able to do the following:
- Obtain targeted biopsies of the hypoxic areas and none hypoxic areas and correlate them with gold standard marker of tissue hypoxia by immunohistochemistry for hypoxia induced factor-1α (HIF-1α).
- Draw Volumes of interests (VOI) over areas >0.5-cm3 (amenable to accurate intra-operative O2 measurement) with the lowest and highest oxygen saturation (SO2) values. VOIs will be then imported into the neuronavigation system (Stryker) for targeted placement of clinically approved Licox® oxygen-sensing probe (Integra NeuroSciences).
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult (>18 year old) patients with newly diagnosed GBM presenting to our centre for surgical management and post-operative chemoradiation
- Creatinine clearance > 60 ml/minute
- Able to tolerate an MR scan
- Capable of providing informed consent.
Exclusion Criteria:
- Prior brain surgery or radiation
- History of liver disease requiring liver MRI (due to accumulation of ferumoxytol in Kupffer cells which can affect liver MRI for up to 3 months)
- On more than two antihypertensive medications
- History of allergy or adverse reaction to iron supplements
- Prior treatment with ferumoxytol
- Large (>50%) hemorrhagic component in the solid enhancing part of the tumor
- Need for emergency craniotomy.
- Pregnant patients
- Breast feeding
- Serum ferritin of >800 ng/mL
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single patient group receiving Feraheme®
Newly diagnosed GBM patients with no prior treatment will receive Feraheme® as MRI contrast agent
|
Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oxygen saturation in GBM with qBOLD MRI and its correlation with histological markers of tissue hypoxia and angiogenesis
Time Frame: Within 8 hours after the MRI exam is complete
|
Pre-operative qBOLD imaging and O2 saturation mapping will be performed in 27 newly diagnosed GBM patients and targeted biopsies will be obtained from the hypoxic and non-hypoxic regions of the tumor.
|
Within 8 hours after the MRI exam is complete
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oxygen saturation in GBM with qBOLD MRI and its correlation with targeted intraoperative oxygen measurement
Time Frame: Within 8 hours after the MRI exam is complete
|
Volumes of interest from the hypoxic and non-hypoxic regions of the tumor will be imported into the neuronavigation system (Stryker) for targeted placement of Licox® oxygen-sensing probe (Integra NeuroSciences).
|
Within 8 hours after the MRI exam is complete
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Pejman Jabehdar Maralani, MD FRCPC, Sunnybrook Health Sciences Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Signs and Symptoms, Respiratory
- Glioblastoma
- Hypoxia
- Hematinics
- Pharmaceutical Solutions
- Parenteral Nutrition Solutions
- Ferrosoferric Oxide
Other Study ID Numbers
- 127-2014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoxia
-
Western University, CanadaUnknownBrain Hypoxia IschemiaCanada
-
Yale UniversityTianjin Chest HospitalCompletedBrain Ischemia Hypoxia | Muscle; Ischemic | Muscle HypoxiaChina
-
Fliegerärztliches InstitutCompleted
-
University of Texas at AustinCompletedIntermittent HypoxiaUnited States
-
Owlet Baby Care, Inc.Completed
-
Robert L. OwensCompletedIntermittent HypoxiaUnited States
-
Montreal Heart InstituteUniversité de MontréalCompleted
-
United States Army Research Institute of Environmental...University of Puget SoundRecruiting
-
The University of Hong Kong-Shenzhen HospitalRecruiting
-
Sherief Abd-ElsalamRecruiting
Clinical Trials on Feraheme®
-
University of Wisconsin, MadisonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedObesity | Pregnancy | PreeclampsiaUnited States
-
Brigham and Women's HospitalCompletedPulmonary EmbolismUnited States
-
Oregon Health and Science UniversityNational Institute of Neurological Disorders and Stroke (NINDS)TerminatedNervous System Diseases | Diagnostic ImagingUnited States
-
Brigham and Women's HospitalActive, not recruiting
-
Jason GagliaHarvard Medical School (HMS and HSDM); National Institute of Allergy and Infectious...Unknown
-
University of HawaiiOregon Health and Science UniversityCompletedHIV DementiaUnited States
-
Beau NakamotoNational Institute of Neurological Disorders and Stroke (NINDS); University... and other collaboratorsCompleted
-
Georges OuelletCompletedInflammation | Oxidative Stress | Iron-Deficiency AnemiaCanada
-
Paul FinnCompletedPediatric Congenital Heart DiseaseUnited States
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnGlioblastoma Multiforme | Brain Tumor, Recurrent | Brain Tumor, Primary | Brain Tumor, Adult: GlioblastomaUnited States